Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody

Executive Summary

Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.


Related Content

Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
The NASH Pipeline: Replete With Targets And New Compounds
Conatus' Liver Focus Goes Well Beyond NASH
Macrocure's CureXcell Phase III Leg Ulcer Study Futile
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
Exalenz Of Israel, Pfizer Of U.S. In Deal With FDA-Approved Test Kit


Related Companies

Related Deals